Insys Therapeutics, Inc.
INSY
INSY was delisted on the 18th of June, 2019.
138 hedge funds and large institutions have $592M invested in Insys Therapeutics, Inc. in 2016 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 59 increasing their positions, 38 reducing their positions, and 35 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 38
6% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $12.7M
10% less funds holding
Funds holding: 154 → 138 (-16)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 35
49% less capital invested
Capital invested by funds: $1.15B → $592M (-$558M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$58.6M |
| 2 |
1WCM
12 West Capital Management
New York
|
+$11.8M |
| 3 |
FHAM
Folger Hill Asset Management
New York
|
+$7.95M |
| 4 |
Bank of New York Mellon
New York
|
+$6.43M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$5.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$73.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$23.5M |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$22.8M |
| 4 |
NCGI
Next Century Growth Investors
Plymouth,
Minnesota
|
-$22.3M |
| 5 |
VM
Valinor Management
New York
|
-$16.8M |
INSY Hedge Fund Activity: Q1 2016 in Review
138 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Insys Therapeutics, Inc. (INSY) for Q1 2016, worth a combined $592M — down 49% from $1.15B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of INSY and 21 opened new positions — a net loss of 14 holders — while 38 trimmed existing stakes and 59 added.
The largest buyer was Scopia Capital Management, adding an estimated $58.6M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $73.5M sold.
- 138 institutional investors held Insys Therapeutics, Inc. (INSY) as of Q1 2016, down from 154 in Q4 2015.
- Funds reported $592M of Insys Therapeutics, Inc. stock for Q1 2016, down 49% quarter-over-quarter.
- 21 funds opened new Insys Therapeutics, Inc. positions in Q1 2016 and 35 closed out, a net change of -14 holders.
- The largest Insys Therapeutics, Inc. buyer in Q1 2016 was Scopia Capital Management, an estimated $58.6M added.
- The largest Insys Therapeutics, Inc. seller in Q1 2016 was Consonance Capital Management, an estimated $73.5M sold.
Based on aggregated 13F filings for Q1 2016.